

Protalix BioTherapeutics, Inc.  
Form 8-K  
February 16, 2017

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): February 16, 2017**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

**Delaware  
(State or other jurisdiction  
of incorporation)**

**001-33357**

**(Commission File Number)**

**65-0643773  
(IRS Employer**

**Identification No.)**

**2 Snunit Street**  
**Science Park, POB 455**  
**Carmiel, Israel**  
**(Address of principal executive offices) (Zip Code)**

**20100**

**Registrant's telephone number, including area code +972-4-988-9488**

**(Former name or former address, if changed since last report.)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01. Regulation FD Disclosure**

On February 13, 2017, Protalix BioTherapeutics, Inc. (the “Company”) announced that the Company was going to participate in the Lysosomal Disease Network 13<sup>th</sup> Annual *WORLDSymposium*<sup>TM</sup> 2017 being held February 13 through 17, 2017 in San Diego, CA. Positive data from the Company’s phase I/II dose-ranging clinical trial of PRX-102 for the treatment of Fabry disease was presented at the symposium.

Dr. Yoseph Shaaltiel, the Company’s Executive Vice President, Research & Development, gave an oral presentation entitled “Characterization of a chemically modified plant cell culture expressed human  $\alpha$ -galactosidase-A enzyme for treatment of Fabry disease.”

Dr. Derralynn Hughes of the Lysosomal Storage Disease Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK, and a principal investigator in the Company’s clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease, gave an oral presentation entitled “One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy.” Dr. Hughes also gave a poster presentation of the same title.

Prof. David Warnock, Professor of Nephrology at the University of Alabama Birmingham, Birmingham, Alabama, gave an oral presentation entitled “PRX-102 for treating Fabry disease – immunogenicity and PK results from a phase 1-2 study.” Prof. Warnock also gave a poster presentation of the same title.

The presentations and posters featuring the data will be available on the Company’s website, under the Presentations tab.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PROTALIX  
BIOTHERAPEUTICS, INC.**

Date: February 16, 2017 By: /s/ Moshe Manor  
Name: Moshe Manor  
Title: President and  
Chief Executive Officer